Elrexfio Market Report 2026

Elrexfio Market Overview

• The Elrexfio market growth in the historic period has been driven by limitations of conventional chemotherapy, growth in lymphoma incidence • Market expansion is supported by rising adoption of immunotherapies, expansion into additional indications • Growth Driver: Impact Of Rising Multiple Myeloma Prevalence On The Growth Of The Market • Market Trend: Advancements In BCMA Targeted Therapy For Cancer And Autoimmune Diseases • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Elrexfio Market?

Elrexfio is the brand name for epcoritamab, a monoclonal antibody used for the treatment of relapsed or refractory B-cell malignancies, particularly B-cell non-Hodgkin lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL). Epcoritamab targets and kills cancerous B-cells by engaging CD3 on T-cells and CD20 on B-cells. The main types of indications for elrexfio are multiple myeloma and other hematologic cancers. Multiple myeloma is a blood cancer of plasma cells in the bone marrow, causing immune, bone, and organ damage, treatable with therapies like Elrexfio targeting BCMA. It is distributed by several distribution channels, such as hospital pharmacies, retail pharmacies, and online pharmacies, and used by various end users including hospitals, specialty clinics, research institutions, and others.

What Is The Elrexfio Market Growth Forecast?

The growth in the forecast period can be attributed to rising adoption of immunotherapies, expansion into additional indications, growth in precision oncology, increasing investment in biologics, improved patient survival outcomes. Major trends in the forecast period include bispecific antibody adoption, expansion of immuno oncology therapies, rising use in refractory lymphomas, preference for targeted cancer treatments, advancement in t cell engaging therapies.

Global Elrexfio Market Segmentation

1) By Indication: Multiple Myeloma, Other Hematologic Cancers 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 3) By End User: Hospitals, Specialty Clinics, Research Institutions, Other End Users

What Are The Drivers Of The Elrexfio Market?

The rising prevalence of multiple myeloma is expected to propel the growth of the elrexfio market going forward. Multiple myeloma is a type of cancer that forms in a kind of white blood cell called plasma cells, which are found in the bone marrow, and it leads to abnormal growth and accumulation of these cells, causing damage to bones, kidneys, and other organs. The prevalence of multiple myeloma is attributed to factors such as an aging population, increasing awareness and advancements in diagnostic techniques, and improved healthcare access that allows for better detection of the disease. Elrexfio (elranatamab) is a monoclonal antibody that helps treat multiple myeloma by targeting and binding to the BCMA (B-cell maturation antigen) protein on the surface of myeloma cells, thereby promoting immune system activation to destroy these cancer cells. For instance, in February 2023, according to Cancer Research UK, a UK-based research organization, the annual number of new myeloma cases in the UK is expected to increase from approximately 6,800 cases between 2023-2025 to around 8,300 between 2038 and 2040. Therefore, the rising prevalence of multiple myeloma is driving the growth of the elrexfio industry. The rise in healthcare expenditures is expected to propel the growth of the elrexfio market going forward. Health expenditures refer to all costs associated with providing health services, family planning activities, nutrition programs, and emergency help with a focus on health. Healthcare expenditures increased primarily because the rising prevalence of chronic diseases led to greater demand for continuous treatments, long-term medications, and frequent medical visits. Higher healthcare expenditures support the uptake of Elrexfio by enabling greater investment in advanced oncology therapies, allowing healthcare systems to allocate more resources toward novel bispecific treatments for multiple myeloma. For instance, in May 2025, according to Statistics Netherlands, a Netherlands-based national statistical office, the Netherlands spent approximately 130.70 billion dollars on health care in 2024, which was 9.79 billion dollars or 8.1 percent more than in 2023. Therefore, the rise in healthcare expenditures is driving the growth of the elrexfio industry.

Key Players In The Global Elrexfio Market

Major companies operating in the elrexfio market are Pfizer Inc.

Global Elrexfio Market Trends and Insights

The ket trend in the elrexfio market is focusing on developing advanced therapies such as B-cell maturation antigen-targeted therapy to enhance treatment efficacy for cancer and autoimmune diseases. B-cell maturation antigen (BCMA) targeted therapy is a type of cancer treatment specifically targeting the BCMA protein found on the surface of malignant plasma cells, such as those in multiple myeloma. For instance, in August 2023, Pfizer Inc., a US-based pharmaceutical and biotechnology company, received approval from the U.S. Food and Drug Administration (FDA) for elranatamab-bcmm (Elrexfio). Elranatamab-bcmm (Elrexfio) is a bispecific T-cell engager therapy that targets B-cell maturation antigen (BCMA) on multiple myeloma cells and CD3 on T-cells, helping to activate the immune system to fight relapsed or refractory multiple myeloma in adults who have undergone various lines of prior treatment.

Regional Insights

North America was the largest region in the elrexfio market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Elrexfio Market?

The elrexfio market consists of sales of combination therapies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Elrexfio Market Report 2026?

The elrexfio market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the elrexfio industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.